Abstract | BACKGROUND: METHODS: RESULTS: Both groups had similar baseline characteristics. During follow-up, there was no difference between the two groups in terms of death (6.5% for SES and 10.4% for PES, p = 0.22), MI (2.6% vs. 3.9%, p = 0.75), stent thrombosis (1.9% vs. 3.2%, p = 0.72), TVR (3.9% vs. 8.4%, p = 0.15) and MACE (12.3% vs. 18.8%, p = 0.12). Eight patients in overall population had stent thrombosis: definite 3, probable 1, and possible 4. Cumulative incidence of stent thrombosis was gradually increased; 0.6% at 30 days, 0.6% at 1 year, 1.6% at 2 years, and 2.6% at 3 years. Very late stent thrombosis, definite or probable, occurred in 0.6% for both. CONCLUSION: Among non-selected STEMI patients who underwent primary angioplasty, both SES and PES might be safe and SES showed similar three-year clinical outcomes compared to PES.
|
Authors | Hyun-Sook Kim, Jae-Hwan Lee, Seung-Whan Lee, Young-Hak Kim, Jae-Hyeong Park, Si-Wan Choi, Jin-Ok Jeong, In-Whan Seong, Kyoung-Suk Rhee, Jae-Ki Ko, Sang-Ho Jo, Young Jin Choi |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 147
Issue 2
Pg. 253-7
(Mar 03 2011)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 19783056
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2009 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Immunosuppressive Agents
- Tubulin Modulators
- Paclitaxel
- Sirolimus
|
Topics |
- Angioplasty, Balloon, Coronary
(adverse effects, mortality)
- Cause of Death
- Coronary Restenosis
(mortality)
- Disease-Free Survival
- Drug-Eluting Stents
(adverse effects, statistics & numerical data)
- Electrocardiography
- Follow-Up Studies
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Incidence
- Kaplan-Meier Estimate
- Myocardial Infarction
(diagnosis, mortality, therapy)
- Paclitaxel
(therapeutic use)
- Randomized Controlled Trials as Topic
(mortality)
- Sirolimus
(therapeutic use)
- Tubulin Modulators
(therapeutic use)
|